01 4AcipHex
02 1Aciphex
03 7Pariet
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2020 Revenue in Millions : 38
2019 Revenue in Millions : 39
Growth (%) : -2
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2020 Revenue in Millions : 188
2019 Revenue in Millions : 200
Growth (%) : -6
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2021 Revenue in Millions : 60
2020 Revenue in Millions : 180
Growth (%) : -64
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2021 Revenue in Millions : 24
2020 Revenue in Millions : 36
Growth (%) : -30
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2022 Revenue in Millions : 12
2021 Revenue in Millions : 60
Growth (%) : -80
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2023 Revenue in Millions : 129
2022 Revenue in Millions : 169
Growth (%) : -14
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2017 Revenue in Millions : 256
2016 Revenue in Millions : 285
Growth (%) : -10
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2018 Revenue in Millions : 205
2017 Revenue in Millions : 240
Growth (%) : -15%
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2017 Revenue in Millions : 62
2016 Revenue in Millions : 68
Growth (%) : -8
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2018 Revenue in Millions : 44
2017 Revenue in Millions : 59
Growth (%) : -25%
LOOKING FOR A SUPPLIER?